Innoviva, Inc.

INVA • Biotechnology

$21.33

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$1.57B

Crecimiento

—

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 63.8%Crecimiento positivo de ingresos · 7.2%Flujo de caja libre positivo · 2.91Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 4.97

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 1:05 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$21.33

Change0.00%

Shares Out73.42M

Market Cap$1.57B

Enterprise Value$1.25B

52W Range16.52 - 25.15

Beta0.34

P/E4.38

P/S3.53

P/B1.27

P/FCF7.02

EV/Sales2.81

Price$21.33

Change0.00%

Shares Out73.42M

Market Cap$1.57B

Enterprise Value$1.25B

52W Range16.52 - 25.15

Beta0.34

P/E4.38

P/S3.53

P/B1.27

P/FCF7.02

EV/Sales2.81

EV/EBITDA2.99

EV/FCF5.58

Earnings Yield22.81%

FCF Yield14.25%

Dividend Yield0.00%

Gross Margin72.33%

Oper. Margin38.52%

Profit Margin63.78%

Debt/Eq0.23

Current Ratio14.64

Quick Ratio13.85

Target$38.00

Target Upside78.15%

Target Median$38.00

Target Range34.00 - 42.00

Volume1.29M

Avg Volume818.34K

EPS Surprise0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

85/100

Fortaleza financiera

Deuda, caja, estabilidad

93/100

Potencial de crecimiento

Ingresos y expansión

51/100

Atractivo del precio

Barata o cara hoy

91/100

Por qué este puntaje▼

Márgenes estables o en mejora · 63.8%Crecimiento positivo de ingresos · 7.2%Flujo de caja libre positivo · 2.91Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 4.97Nivel de deuda manejable · 0.23

Analyst view

Analyst sentiment and price target

INVA

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

70/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$32.00

Promedio

$37.00

Mediana

$37.00

Alto

$42.00

Resumen de la compañía

IPO: 10/5/2004

Industria: Biotechnology

P/B i: 1.27

Deuda / Patrimonio i: 0.23

Margen operativo: 38.52%

Margen neto: 63.78%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.23

Ratio corriente: 14.64

Ratio rápido: 13.85

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Zhen Marianne

Transacción: 05/20/2026

VENTA

Cambio

-1,127

Precio

$22.24

Presentación

05/22/2026

Tipo

VENTA

Raifeld Pavel

Transacción: 05/20/2026

VENTA

Cambio

-1,130

Precio

$22.24

Presentación

05/22/2026

Tipo

VENTA

Basso Stephen

Transacción: 05/20/2026

VENTA

Cambio

-559

Precio

$22.24

Presentación

05/22/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Zhen Marianne	VENTA	-1,127	$22.24	05/20/2026	05/22/2026
Raifeld Pavel	VENTA	-1,130	$22.24	05/20/2026	05/22/2026
Basso Stephen	VENTA	-559	$22.24	05/20/2026	05/22/2026
Raifeld Pavel	COMPRA	+1,123	Not reported	05/15/2026	05/22/2026
Basso Stephen	COMPRA	+1,123	Not reported	05/15/2026	05/22/2026
Linden Josephine	OTRO	0	Not reported	05/18/2026	05/20/2026
Linden Josephine	COMPRA	+9,166	$21.80	05/18/2026	05/20/2026
Linden Josephine	COMPRA	+5,733	Not reported	05/18/2026	05/20/2026
Haimovitz Jules	COMPRA	+10,000	$22.99	05/04/2026	05/06/2026
Haimovitz Jules	COMPRA	+9,786	Not reported	05/04/2026	05/06/2026
Small Derek A	COMPRA	+10,000	$22.99	05/04/2026	05/06/2026
Small Derek A	COMPRA	+9,786	Not reported	05/04/2026	05/06/2026
Basso Stephen	COMPRA	+37,994	Not reported	05/04/2026	05/06/2026
Basso Stephen	COMPRA	+93,750	$22.99	05/04/2026	05/06/2026
Schlesinger Sarah J.	COMPRA	+10,000	$22.99	05/04/2026	05/06/2026
Schlesinger Sarah J.	COMPRA	+9,786	Not reported	05/04/2026	05/06/2026
Zhen Marianne	COMPRA	+31,500	$22.99	05/04/2026	05/06/2026
Zhen Marianne	COMPRA	+12,766	Not reported	05/04/2026	05/06/2026
DiPaolo Mark	COMPRA	+10,000	$22.99	05/04/2026	05/06/2026
DiPaolo Mark	COMPRA	+9,786	Not reported	05/04/2026	05/06/2026

Sobre la compañía

Innoviva, Inc.

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Fuente - Link

Competidores

ATAI CVAC DNTH ELVN IMTX INBX MDXG NKTR RLAY SNDX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Innoviva to Participate in Upcoming Investor Conferences

Innoviva, Inc. (NASDAQ: INVA) (âInnovivaâ or the âCompanyâ), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical

GuruFocus

Hsbc Holdings PLC Buys Shares of 49,428 Innoviva, Inc. $INVA

Hsbc Holdings PLC acquired a new position in Innoviva, Inc. (NASDAQ: INVA) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 49,428 shares of the biotechnology company's stock, valued at approximately $843,000. Hsbc Holdings PLC owned 0.07% of Innoviva as of its most

Defense World

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company's infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics prod.

Business Wire

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.

Seeking Alpha

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-06	0.43	0.44	0.01
2026-02-25	0.34	1.94	1.6
2025-11-05	0.46	1.08	0.62
2025-08-06	0.57	0.77	0.2
2025-05-07	0.29	0.25	-0.04
2025-02-26	0.34	0.57	0.23
2024-11-06	0.27	0.02	-0.25
2024-07-31	0.24	0.68	0.44
2024-05-08	0.17	0.46	0.29
2024-02-29	0.23	0.76	0.53
2023-11-01	0.27	0.98	0.71
2023-08-02	0.26	0.08	-0.18